@article{Scrivo_Conti_Spinelli_Truglia_Magrini_Di Franco_Ceccarelli_Valesini_2009, title={Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature}, volume={61}, url={https://www.reumatismo.org/reuma/article/view/reumatismo.2009.107}, DOI={10.4081/reumatismo.2009.107}, abstractNote={The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not respond or show suboptimal response to the currently available anti- TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events.}, number={2}, journal={Reumatismo}, author={Scrivo, R. and Conti, F. and Spinelli, F.R. and Truglia, S. and Magrini, L. and Di Franco, M. and Ceccarelli, F. and Valesini, G.}, year={2009}, month={Jun.}, pages={107–117} }